Callisto Stockholders Approve Merger With Synergy Pharmaceuticals

News provided by
Callisto Pharmaceuticals
Jan. 15, 2013 19:00
NEW YORK--(Korea Newswire)--Callisto Pharmaceuticals, Inc. (OTCQB:CLSP) (“Callisto”) today announced that it convened its special meeting of stockholders yesterday and it has received the necessary approvals from its stockholders to authorize Callisto's merger with and into Synergy Pharmaceuticals Inc. (“Synergy”) pursuant to the previously announced Agreement and Plan of Merger, dated July 20, 2012, as amended on October 15, 2012. Callisto and Synergy expect to close the merger as soon as practicable.

About Callisto Pharmaceuticals Inc.

Callisto is a development stage biopharmaceutical company. All of Callisto's drug candidates, currently plecanatide and SP-333 to treat GI disorders and diseases, are being developed exclusively by Synergy.

Contact

Investor Contact:
Danielle Spangler
The Trout Group
Send Email
(646) 378-2924

This news is a press release provided by Callisto Pharmaceuticals.

Callisto Pharmaceuticals News Releases
Callisto Announces Adjournment of Special Meeting
Callisto Pharmaceuticals, Inc. (OTCBB:CLSP) (“Callisto”) today announced that it convened its special meeting of stockholders on Thursday, January 3, 2013 and adjourned the meeting until Monday, January 14, 2013, at 1:00 p.m., Eastern Standard Time. The special meeting was adjourned to ...
2013년 1월 4일 08:33
More News
Health Biotechnology Pharmaceutical Mergers & Acquisitions Overseas
Callisto Pharmaceuticals
Follow
News Releases RSS Feed

국내 최대 배포망으로 보도자료를 배포하세요

지금 시작하기